Abstract. Anal cancer comprises malignancies of the anal canal principally of two morphologic variants: squamous cell carcinoma (SCC) and adenocarcinoma. In most settings, SCC compromises more than 70% of cases. In the general population, anal cancer is uncommon, with age-standardised incidence rates mostly between 1 and 2 per 100 000 per year. However, incidence of anal SCC is increasing by 1-3% per year in developed country settings. High-risk human papillomavirus (HPV) types can be detected in 80-90% of all anal SCC cases, making it second only to cervical cancer in the closeness of its association with this virus. HPV-16 can be detected in~90% of HPV-positive cases of anal SCC. Case-control studies have demonstrated that sexual risk factors (homosexuality in men and multiple sexual partners in women) are strongly associated with anal cancer risk. Other risk factors include immune deficiency and tobacco exposure. Anal cancer rates are highest in homosexual men, particularly in those who are HIV-positive, in whom anal cancer is among the most common of all cancers. Vaccination against HPV holds great promise for anal cancer prevention for those not already HPV-infected. For the current generation of adult high-risk populations, screening programs to allow early detection and treatment are under investigation.
Introduction
Anal cancers comprise a group of uncommon, mostly human papillomavirus (HPV) related cancer types arising from the squamous and glandular epithelia of the anus. Anatomical and histological differences in cellular origin mean that anal cancer in fact mainly comprises two different cancer types, squamous cell carcinoma (SCC) and adenocarcinoma, and this needs to be considered when reviewing published data in this field. In Australia, anal cancer is rare in the general population but the annual incidence is increasing rapidly. 1 In recent years, an increased research focus on anal cancer has arisen from a clearer understanding that the cancer is much more common in some subsets of the population, particularly homosexual men, 2 and is potentially preventable by the newly available HPV vaccines. 3 
Classification

Anatomic site
For therapeutic reasons, it is important to distinguish anal cancer from cancer of the perianal skin. Perianal skin cancers have a better prognosis and may sometimes be treated with simple excision, 4 whereas anal cancers generally require combined chemoradiotherapy as first-line treatment. 5 Aetiologically, both sites are associated with HPV infection, but some limited data suggest that cancer of the peri-anal skin is less consistently HPV-related than is cancer which arises from the anal canal. 6 Cancer masses often involve both areas at the time of diagnosis. 5 Historically, the delineation between 'anal cancer' and 'skin cancer' has been somewhat unclear, with no generally accepted definition of the outer limit of the anal canal. A new pragmatic definition has recently been proposed:
'A tumour of the anal canal is defined as a tumour that cannot be seen in its entirety, or at all, when gentle traction is placed on the buttocks.' 5 The restriction of the definition to masses that involve the anal canal means that it is likely that sometimes, more distal HPVassociated cancers of the anal region are coded as skin cancers and not included in cancer registry data on anal cancer.
Consequently, cancer registry data probably under-represent the total burden of HPV-associated malignancies of the anal region. The magnitude of this under-representation is uncertain.
Morphological coding
In the anal canal, the mucosal lining undergoes a transition from the columnar epithelia of the rectum to squamous epithelia. The two main histological subtypes of anal cancer arise from these two cell types (adenocarcinoma and SCC respectively). Although SCC is generally the most common subtype, the proportions of the two subtypes have varied in recent reviews. The proportion of all anal cancer due to adenocarcinoma in recent reports from industrialised countries has varied from 14% in the United States (US) 7 to 21% in Scotland 8 and 27% in Australia. 1 In some countries, nonsquamous variants comprise the majority of anal cancers. The delineation between subtypes is important because, based on limited data, it appears that adenocarcinoma is less closely related to HPV infection 1, 9 and, in many cases, may represent a downward extension of rectal cancer. 5 For this reason, it has been recommended that these two most common variants of anal cancer be considered separately in epidemiological analyses. 6 Unfortunately, many papers published in the field do not follow this rule. Where available, this paper presents the data for these two subtypes separately, but data on all anal cancer are presented where the subtypes have not been separated.
Incidence
Anal cancer is a rare cancer in the general population globally, with annual age-adjusted incidence rates of all types combined of less than 2 per 100 000 in almost all countries that have reported rates. 6, 10 There is some variation in the pattern by gender, with some countries showing a male excess and some countries showing a female excess. 6 Incidence increases exponentially with age, with annual anal SCC rates greater than 5 per 100000 reported in those Australians aged more than 65. 1 In Australia, 48% of cases are diagnosed in people aged over 65 years. 1 
Time trends
In all recent reports of time trends in the incidence of anal SCC, there have been marked increases in the rate of anal SCC over recent decades. In Denmark, the increase in anal SCC commenced in the 1960s and was much greater in women than men, and in residents of Copenhagen. 11, 12 In the US in the period 1998-2003, anal SCC incidence increased by an average of 2.6% per year, and this trend was similar in men and women. 7 In Scotland during 1975-2002, incidence rates of anal SCC increased by more than twofold in each sex. 8 In Australia, incidence rates of anal SCC increased by 3.4% per year in males and 1.9% in females in the period 1982-2005, and smaller increases were also seen for anal adenocarcinoma. 1 In the United Kingdom, the incidence of all anal cancer combined increased in both men and women in the period 1960-2004. The increase was larger in women. 13 The increasing incidence of anal SCC in the general population may be related to changing sexual practices over time, such as earlier age of first sexual intercourse and higher number of lifetime sex partners.
Risk factors
Only five case-control studies have examined risk factors for anal cancer. The first, published in 1987, included all types of anal cancer without differentiation of type; 14 three included only anal SCC and its variants, [15] [16] [17] and only one included both SCC and adenocarcinoma. 9 The latter study presented odds ratios for anal SCC only, as numbers of adenocarcinoma cases were too small. For this reason, the results presented below can be interpreted as applying to anal SCC but, for the most part, not anal adenocarcinoma.
Human papillomavirus infection
HPV has been classified by the International Agency for Research on Cancer as a human carcinogen for several cancer types, including anal cancer. 18 In a recent meta-analysis, it was reported that HPV can be detected in 84% of anal SCC specimens, 19 which puts anal cancer second only to cervical cancer in the strength of its association with HPV. HPV prevalence was similar in the two main subtypes of anal SCC, basaloid and large cell SCC. Given the limitation of the analytic techniques, it may be that HPV is a necessary cause of anal SCC, as it is for cervical cancer. 9 There are very limited data on HPV prevalence in anal adenocarcinoma, but two reports, based on inclusion of a total of only 27 cases, have found that around 40% of these cases are HPV-positive. 9, 20 Compared with cervical cancer, HPV-16 is more common (70% or more of all SCC cases, close to 90% of all HPV-positive cases) and HPV-18 less common (less than 10%) in anal cancer. 19, 20 The presumed precursor of anal cancer, highgrade anal intraepithelial neoplasia, is also usually caused by HPV. HPV-16 is more strongly related to higher-than lowergrade anal lesions and, as mentioned, even more strongly related to cancer. This suggests that the risk of progression for HPV-16 related lesions is higher than for other HPV types.
Sexual risk factors
As anal infection with HPV is the underlying cause of most anal SCC, it is not surprising that anal sexual exposure to HPV is a strong risk factor for anal SCC.
In men, a history of homosexuality has been consistently described as being related to anal cancer. This was suggested by case series as early as the late 1970s 21 and has been confirmed in cancer registration data that demonstrated higher incidence rates of anal cancer in never-married as compared with married men 22, 23 and in case-control studies of anal SCC risk among men 9, 14, [15] [16] [17] . A history of receptive anal intercourse has been found to be a strong risk factor in all studies that have reported on this behaviour, increasing the risk of anal SCC by up to 50-fold. 9, 14, 15, 17 Nevertheless, in each of the five case-control studies that included men, fewer than 50% of anal SCC cases were in men who reported a history of homosexual contact. 9, [14] [15] [16] [17] Although it is likely that some men with anal SCC in these studies under-reported a history of homosexual contact because of social approval bias, it is also highly likely that some men acquired anal HPV by means other than by receptive anal intercourse. For other sexually transmissible infections (STIs) such as gonorrhoea (Neisseria gonorrhoeae) and chlamydia (Chlamydia trachomatis), and for genital warts, it has been demonstrated that nonintercourse sexual behaviours, such as digital stimulation of the anus, are independent risk factors. 24, 25 For HPV, a study of patients with genital warts found over one-quarter had the same HPV DNA types detected in genital samples and samples taken from fingertips and fingernails. 26 The exact proportion of anal cancer that occurs in men with no history of homosexual anal sexual contact is unclear, but it appears to be substantial. Additionally, in the case-control studies of anal cancer, HIV status has, in general, not been reported. Thus some of the association with homosexuality may be confounded by the association with impaired immune function (see below). A recent meta-analysis reported there were only two estimates of anal cancer incidence in HIVnegative homosexual men, with an incidence rate of 5 per 100 000 per year.
2 Though this estimate is higher than rates in the general population, the incidence is not as high as would be expected from the odds ratios reported in case-control studies.
In women, the association of anal cancer risk with receptive anal intercourse appears to be weaker than in men. Among case-control studies, most have found significant 7, 20 or nonsignificant 14, 15 positive associations with odds ratios of five or less. Only a minority of women with anal cancer report receptive anal intercourse. All six published case-control studies have reported associations between anal SCC and indirect markers of increased likelihood of HPV exposure, such as a higher number of lifetime sexual partners and a history of STI. 9, [14] [15] [16] [17] 21, 27 In a study of anal HPV acquisition in women, anal HPV was common, and receptive anal intercourse was only weakly associated with acquisition. 28 Thus, in women as in men, it is likely that nonintercourse anal behaviours are important in anal HPV infection. An additional factor may be the physical proximity of the anus to the female genitalia, resulting in the spread of HPV infection. Women who have previously had HPV-related genital disease appear to be at a particularly increased risk of anal cancer. In a Swedish record linkage study, the risk of anal cancer was raised fivefold in women with a previous diagnosis of high-grade cervical intraepithelial neoplasia. 29 In a similar study in the US, the association was even stronger, with the highest relative risk of 22 found for anal cancer after a diagnosis of in situ vulval cancer. 30 
Immune function
People with immune deficiency have increased risk of anal cancer, irrespective of the whether it is HIV-related or due to other causes. As HIV is most commonly acquired sexually, people with HIV frequently have been exposed to other STIs, including anal HPV. In this population, the two exposures of HIV-associated immune deficiency and high rates of HPV infection lead to a greatly increased relative risk of anal cancer, estimated to be~30-fold. 31 The relative risk is highest in homosexual men, but the risk is also raised 10-fold or more in heterosexual women with HIV and in other risk groups. 32 Anal HPV can be detected in the majority of HIV-positive homosexual men, and a recent meta-analysis estimated that almost 30% have high-grade anal intraepithelial neoplasia. 2 Annual crude incidence rates of anal cancer in HIV-positive homosexual men have reached 78 per 100 000 in the era since introduction of highly active antiretroviral therapy. 2 Crude incidence in this population in one large North American cohort has now reached 131 per 100 000. 33 This incidence suggests that anal cancer has become one of the most common of any cancers in HIV-positive homosexual men. In people with HIV, it is clear that risk is not as strongly related to immune deficiency as it is for the AIDS-associated cancers non-Hodgkin's lymphoma and Kaposi's sarcoma. Nevertheless, emerging evidence does suggest that anal cancer risk is higher in those with a low current or nadir CD4 count. 34, 35 Organ transplant recipients are required to take lifelong immune suppressive medications. In a recent meta-analysis, rates of anal cancer were increased around fivefold in this population. 31 In other immune deficient states, such as after certain haematological malignancies, there is a lesser increase in risk, which is of borderline statistical significance. 36 
Smoking
In most cultures, cigarette smoking has been correlated with increased sexual activity. 37 For this reason, it is to be expected that cigarette exposure will be univariately associated with anal cancer risk, due to confounding. However, in addition to the confounding effect, large-scale studies of the association between tobacco exposure and cervical cancer risk in women who are infected with HPV have demonstrated an independent effect, and an association with the duration and intensity of tobacco exposure. 38 Possible mechanisms include an exposure to carcinogens in cervical secretions and an immunosuppressive effect. 38 Tobacco smoking has been reported to be associated with risk of anal cancer in univariate analyses in all studies which have examined this association. 9, 14, 15, 17, 27, 39 Two studies with careful control for confounders did report an association at the multivariate level, 9, 39 suggesting that, as in cervical cancer, smoking may be an independent risk factor.
Summary
Anal cancer remains a relatively uncommon cancer in the general population, but is increasing in incidence in all jurisdictions where trends have been described. As it appears likely that anal HPV is a necessary cause, it is possible that population changes in sexual behaviour may underly these recently observed increases. Certain subgroups of the population are at greatly heightened risk. In homosexual men, anal cancer is relatively common; in HIV-positive homosexual men, it is one of the most commonly occurring cancers. The risk of anal cancer is also increased in the immunosuppressed (including those infected with HIV) and in women with a history of HPV-associated genital precancerous lesions.
HPV vaccination of men and women holds great promise for anal cancer prevention, but as efficacy is greatest if it is administered before the onset of sexual activity, vaccinationassociated reductions in anal cancer morbidity will take decades to be maximised. In the near future, anal cancer prevention efforts should focus on the development of a screening program for those at greatest risk in an effort to minimise morbidity and mortality.
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